**FAX FORM TO:** 1.877.597.3070

**PHONE:** 1.800.473.3516

EMAIL: <a href="mailto:specialty@wellpartner.com">specialty@wellpartner.com</a>

Complete the following <u>or include demographic s</u>	heet.									
1. PATIENT INFORMATION					2. PRESCRIBER INFORMATION					
Name:					Name:					
Address:				DEA #:	١	IPI #:	#: State Lic. #:			
City, State, ZIP:				Group or Hospital:						
Primary Phone: DOB: / /				Address:						
Alternate Phone: Gender:				City, State, Zip:						
Email:						Fax:				
Primary Language: Last Four of SSN:				Contact Person: Phone:						
3. INSURANCE INFORMATION	I	Fax co	by of <b>preso</b>	cription and ii	nsurance cards	with this form, if avc	nilable (front	and bac	ck)	
Primary Insurance Company Name:				Secondary Insurance Company Name:						
Primary Cardholder Name:				Secondary Cardholder Name:						
Relationship: 🔿 Self 🔿 Spouse/Partner 🔿 Child/Dependent				Relationship: 🔘 Self 🛛 Spouse/Partner 🔵 Child/Dependent					ent	
Phone: Member ID: Group #:			Phone:		Member ID:	Grou	p #:			
4. DIAGNOSIS AND CLINICAL INFORMA	ΓΙΟΝ			1						
Needs by Date: / /	Ship to	D:	O Patient	t Office	e Other:					
Date of Diagnosis: / /	LAB D	ATA								
			Baseline	Lab Value	Date	Baseline Lab Val	ue Dat	e		
<ul> <li>B18.1 Chronic viral hepatitis B w/o delta-agent</li> <li>B18.2 Chronic viral hepatitis C</li> </ul>	HIV RN	IA:			/ /			/ /		
<ul> <li>R64 Cachexia (HIV wasting)</li> <li>Other (Specify):</li> </ul>	CD4/T	cell:								
Treatment: Naïve Experienced	Hgb:				/ /			/ /		
Height (in/cm): Weight (lb/kg): BMI:				Results:	Date: / /					
Theight (in) ett). Weight (to) kg).		Allergies:								
	Other N	Medicati	ons:							
5. PRESCRIPTION INFORMATION										
Medication Dose/Strength Direct	ons	Qty	Refills	Medication	Dose/Strer	gth Directions		Qty Re	efills	
Atripla 300/200/600				Procrit						

<b>O</b> 1 1011					1	
<ul> <li>Combivir</li> </ul>	300/150	🔵 Reyataz				
Complera	300/200/25	<ul> <li>Selzentry</li> </ul>				
<ul> <li>Descovy</li> </ul>		🔘 Stribild	150/150/200/300			
<ul> <li>Edurant</li> </ul>		🔵 Sustiva				
<ul> <li>Emtriva</li> </ul>	200 mg	<ul> <li>Tivicay</li> </ul>				
<ul> <li>Epivir</li> </ul>		<ul> <li>Trizivir</li> </ul>	300/150/300			
○ Epzicom <sup>™</sup>	600/300	🔵 Triumeq				
<ul> <li>Evotaz</li> </ul>		🔵 Truvada	300/200			
🔵 Genvoya		🔵 Tybost				
<ul> <li>Intelence</li> </ul>	100 mg	Videx EC				
<ul> <li>Isentress</li> </ul>	400 mg	<ul> <li>Viracept</li> </ul>				
🔘 Kaletra	200/50	Viramune XR				
🔵 Lexiva	700 mg	<ul> <li>Viread</li> </ul>	300 mg			
<ul> <li>Norvir</li> </ul>	100 mg	🔘 Zerit				
<ul> <li>Odefsey</li> </ul>		🔵 Ziagen				
Precobix		0				
<ul> <li>Prezista</li> </ul>		0				
ncillary supplies and	hits will be provided as needed for administration	1	1	1	·	

Ancillary supplies and kits will be provided as needed for administration.

## K / / X /

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address or telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.